Skip to main content

Table 1 Comparison of demographic data, comorbidities, and laboratory data between cryptogenic hepatocellular carcinoma (HCC) patients and patients with HCC associated with hepatitis B virus infection, hepatitis C virus infection, and alcohol

From: Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma

 

Cryptogenic HCC (n = 35)

HBV-HCC

* p

HCV-HCC

**p

ALC-HCC

***p

  

(n = 321)

 

(n = 69)

 

(n = 55)

 

Age, yr†

68.3 ± 10.5

57.1 ± 10.3

<0.001

68.1 ± 9.0

0.896

65.5 ± 10.0

0.164

Gender, Male††

20 (57.1)

244 (76.0)

0.015

44 (63.8)

0.512

51 (92.7)

<0.001

BMI (kg/m2) †

24.6 ± 3.3

23.4 ± 3.4

0.034

22.2 ± 3.9

0.002

24.0 ± 4.3

0.143

Obesity††

16 (45.7)

85 (26.7)

0.018

13 (18.8)

0.004

12 (21.8)

0.017

Diabetes ††

13 (37.1)

55 (17.1)

0.004

17 (24.6)

0.183

19 (34.5)

0.802

Hypertension ††

20 (57.1)

77 (24.0)

<0.001

32 (46.4)

0.299

18 (32.7)

0.022

Hyperlipidemia††

9 (25.7)

10 (3.1)

<0.001

4 (5.8)

0.004

2 (3.6)

0.003

Follow-up period, mo†

26.1 ± 27.8

28.5 ± 27.0

0.573

29.9 ± 25.1

0.362

29.2 ± 25.6

0.518

Albumin (g/dL) †

3.7 ± 0.5

3.8 ± 0.6

0.346

3.7 ± 0.6

0.780

3.7 ± 0.5

0.545

Bilirubin (mg/dL) †

1.2 ± 0.7

1.6 ± 2.4

0.437

1.8 ± 2.7

0.551

1.6 ± 1.9

0.216

ALP (IU/L) †

123.3 ± 73.3

137.2 ± 97.2

0.555

125.2 ± 63.1

0.728

132.6 ± 91.8

0.855

AST (IU/L) †

83.8 ± 165.4

89.3 ± 140.5

0.342

111.9 ± 114.6

<0.001

53.2 ± 31.9

0.419

ALT (IU/L) †

58.7 ± 99.0

64.4 ± 98.4

0.111

78.6 ± 60.6

0.001

47.4 ± 72.7

0.371

Platelet (103/μL) †† (<10/10 ~ 13/>13)

5/7/23

87/50/182

0.157

19/18/32

0.056

14/9/42

0.263

PT-INR†

1.14 ± 0.16

1.15 ± 0.18

0.897

1.15 ± 0.14

0.791

1.14 ± 0.19

0.593

Hemoglobin (g/dL) †

12.6 ± 2.3

13.6 ± 2.0

0.007

12.8 ± 2.1

0.570

13.1 ± 2.2

0.460

Na (mmol/L) †

137.0 ± 8.8

137.4 ± 9.6

0.551

137.7 ± 4.0

0.535

137.9 ± 3.4

0.340

Creatinine (mg/dL) †

0.9 ± 0.2

1.0 ± 0.3

0.738

1.2 ± 1.0

0.040

1.2 ± 1.0

0.537

C-P class (A/BC) ††

29/6

246/75

0.404

50/19

0.241

40/15

0.268

MELD score†

9.0 ± 2.9

9.6 ± 3.2

0.273

10.2 ± 3.7

0.076

10.5 ± 4.3

0.051

  1. †Expressed as the mean ± standard deviation. ††Expressed as the number of subjects (%).
  2. Values in bold, statistically significant (p < 0.05).
  3. BMI, Body mass index; AST, Aspartate transaminase; ALT, Alanine transaminase; PT-INR, Prothrombin time-international normalized ratio; C-P class, Child-Pugh class; MELD, Model for end-stage liver disease; HBV-HCC, Hepatitis B-associated hepatocellular carcinoma; HCV-HCC, Hepatitis C-associated hepatocellular carcinoma; ALC-HCC, Alcohol-associated hepatocellular carcinoma.
  4. *p: Cryptogenic HCC vs. HBV-HCC.
  5. **p: Cryptogenic HCC vs. HCV-HCC.
  6. ***p: Cryptogenic HCC vs. ALC-HCC.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us